

Predicting vaccine effectiveness in Mpox

Authors: Matthew T. Berry¹, Shanchita R. Khan¹, Timothy E. Schlub^{1,2}, Adriana Notaras¹, Mohana Kunasekaran¹, Andrew E. Grulich¹, C Raina MacIntyre^{1,3}, Miles P. Davenport¹, David S. Khoury¹

Affiliations:

1. Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
2. Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney, Sydney, New South Wales, Australia.
3. College of Public Service & Community Solutions, and College of Health Solutions, Arizona State University, Tempe, United States.

corresponding authors:

David Khoury

Kirby Institute, UNSW Sydney

Kensington, NSW 2052

dkhoury@kirby.unsw.edu.au

Miles Davenport

Kirby Institute, UNSW Sydney

Kensington, NSW 2052

m.davenport@unsw.edu.au

27 **Abstract:**

28 The Modified Vaccinia Ankara vaccine developed by Bavarian Nordic (MVA-BN) was
29 widely deployed to prevent Mpox during the 2022 global outbreak. This vaccine was initially
30 approved for Mpox based on its reported immunogenicity and effectiveness in animal
31 models, rather than evidence of clinical efficacy. However no validated correlate of
32 protection after vaccination has been identified. Here we performed a systematic search and
33 meta-analysis of the available data to test whether vaccinia-binding ELISA endpoint titer is
34 predictive of vaccine effectiveness against Mpox. We observe a significant correlation
35 between vaccine effectiveness and vaccinia-binding antibody titers, consistent with the
36 existing assumption that antibody levels may be a correlate of protection. Combining this
37 data with analysis of antibody kinetics after vaccination, we predict the durability of
38 protection after vaccination and the impact of dose spacing. Although further work is
39 required to validate this correlate, this study provides the first evidence-based approach for
40 using antibody measurements to predict the effectiveness of Mpox vaccination.

41

42 Mpox virus (formerly Monkeypox) is a zoonotic virus endemic in West Africa, with
43 significant outbreaks in 1980-1986 and in 1997-1998¹, resulting in over 20,000 total recorded
44 cases. Prior to 2017, these outbreaks were typically small and initiated by zoonotic
45 transmission followed by self-terminating human-to-human chains of transmission².
46 However, since 2017, there has been a resurgence of Mpox in Nigeria, Democratic Republic
47 of the Congo (DRC) and other parts of Africa, attributed to waning immunity from smallpox
48 vaccines and accumulation of cohorts that have never been vaccinated against smallpox³. In
49 2022, a global outbreak of Mpox resulted in 91000+ confirmed cases in 115 countries and
50 established chains of human-human transmission leading to a renewed focus on vaccination
51 as a preventative measure for Mpox⁴.

52 Although there is no Mpox-specific vaccine, first generation smallpox vaccination was
53 observed to protect individuals against Mpox infection during the 1980-1986 Mpox outbreak
54 in the DRC (then Zaire)⁵⁻⁸, with an estimated vaccine effectiveness of approximately 85%⁵,
55 and this has also been observed in similar subsequent studies⁹⁻¹¹. However, the live-
56 replicating vaccinia vaccines (first and second-generation) have significant risks of serious
57 vaccine adverse events¹², which led to the development of the third-generation Modified
58 Vaccinia Ankara live-attenuated (replication deficient) vaccine (MVA-BN). Prior to the 2022
59 Mpox outbreak, MVA-BN was approved by the FDA for use as a Smallpox and Mpox
60 vaccine (two doses of 1×10^8 TCID via subcutaneous injection). Given the challenge of
61 directly assessing the efficacy of this vaccine in an RCT, regulatory approval was based on
62 demonstrated non-inferior immunogenicity profile and improved safety compared to the
63 second-generation ACAM2000 vaccine¹³. In particular, comparing vaccinia neutralizing
64 antibody titers induced by vaccination of MVA-BN and ACAM2000, it was deemed
65 “reasonable to expect that this regimen of the vaccine is effective in smallpox vaccinia-naïve
66 as well as in smallpox vaccine experienced individuals”¹³. This was supported by studies in
67 nonhuman primates implicating antibodies directly in mediating protection against lethal
68 Mpox challenge¹⁴.

69 Analysis of case data during the 2022 global outbreak indicates that the MVA-BN vaccine is
70 effective for prevention of Mpox¹⁵⁻²⁰, and affirms the decisions to use these vaccines during
71 the outbreaks. However, important questions remain to be addressed. Firstly, how does
72 MVA-BN effectiveness compare with the protection conferred by the live replicating
73 smallpox vaccines, and how many doses are required? Further, is the protection from MVA-
74 BN vaccination expected to be durable, and will further booster doses be required to confer
75 durable protection against Mpox and protect individuals in potential future outbreaks?

76 Here we address these questions by aggregating the available data on the effectiveness of
77 different vaccinia-based vaccination regimes in protection against Mpox. We compare
78 protection from first generation smallpox vaccines with the protection conferred by one or
79 two doses of the MVA-BN vaccine. Further, given the assumed role of antibodies, we
80 aggregate data on vaccinia-specific ELISA endpoint titers (here after referred to as vaccinia-
81 binding titers) after MVA-BN vaccination (which have been shown to correlate with
82 neutralizing antibody titers to Mpox after vaccinia vaccination²¹), and study the relationship
83 between antibody levels and effectiveness. Finally, we analyze the kinetics of antibody decay
84 over time to predict the duration of protection afforded by 1, 2 or 3 doses of vaccination. This
85 work offers a data-driven approach to support public health decision making on Mpox
86 vaccination and boosting campaigns.
87

88 **Results**

89 **Search results of vaccine effectiveness and immunogenicity studies**

90 Our search identified 14 studies of vaccine effectiveness against Mpox that met the inclusion
91 criteria (fig. S1). These studies included analysis of secondary contacts (n=5), case-coverage
92 studies (n=5), a cohort study (n=1), and case-control studies (n=3) (Table S1). Of these
93 studies, seven reported vaccine effectiveness from first generation smallpox vaccination,
94 three determined effectiveness after one-dose of MVA-BN only, and four studies included
95 protection from both one and two doses of MVA-BN. One study by Payne et al.²² was
96 excluded, because a more recent report by the same authors was identified that contained
97 more data¹⁷. Further, another 2 studies^{5,8} were excluded as they were all performed using
98 similar secondary contact data from the Democratic Republic of Congo during the 1980-1986
99 outbreaks and thus we used only the study providing the most detailed disaggregation
100 temporally and by age⁷.


101 Our systematic search for immunogenicity data yielded 27 clinical trials that reported on
102 antibody responses after MVA-BN vaccination (fig. S2). A subset of 12 trials were identified
103 that reported vaccinia-binding titers in healthy individuals²³⁻³⁵, and one further trial was
104 published only on the clinicaltrials.gov database³⁶ (Table S2). These trials used similar
105 methodologies to assess vaccinia-binding, allowing comparison of immunogenicity between
106 trials. Two studies contained data on all three relevant groups (historic smallpox vaccination,
107 1 dose MVA-BN and 2 dose MVA-BN vaccination), and eight studies contained data for
108 both the MVA-BN 1-dose and 2-dose groups.

110 **Vaccine effectiveness against Mpox**

111 Using the studies identified by our systematic search, we performed a meta-analysis to
112 estimate an aggregate vaccine effectiveness (VE). In this analysis, we stratified data by
113 vaccine type (i.e. historic first-generation, or recent 1-dose or 2-dose MVA-BN vaccination),
114 and a hierarchical model structure was used to account for study heterogeneity (fig. 1a and
115 Table S3). Aggregating the available data, we used a Bayesian hierarchical model to obtain
116 best-estimates of the effectiveness for first-generation vaccines (76.5%, CI:59-87%), one
117 dose of MVA-BN (74.2%, CI:57-84%) and two doses of MVA-BN (82.2% CI:69-89%). We
118 observed that one dose of MVA-BN provided lower effectiveness than historic vaccination,
119 whilst two doses provided higher effectiveness, though neither of these results were
120 significant (OR = 1.09, CI:0.55-2.47, OR=0.75, CI: 0.37-1.73, respectively). Importantly, we

121 had limited power to detect such a difference – and this is reflected by the large credible
 122 intervals. Despite the variation in reported VE across different studies (ranging from 35.8-
 123 86.4% for 1 dose and 66-89.5% for 2 doses), we observe a significant benefit of two dose
 124 vaccination over one dose vaccination (OR=0.69 (CI: 0.54-0.86)) – evident because four
 125 studies compared VE after 1 and 2 doses, and all four showed a trend for higher VE after 2
 126 doses (fig. 1b).

127
 128
 129
 130



131
 132
 133 Figure 1: The estimated effectiveness of different Mpxv vaccine regimens. (A) The estimated
 134 effectiveness of first generation (1st Gen) vaccines (n= 5), a single dose of MVA-BN (n = 6), and two
 135 doses of MVA-BN (n=4) are shown. The estimated effectiveness and 95% credible intervals (shapes
 136 and error bars) in each study along with the combined estimates for effectiveness (black circle) for
 137 different regimes are shown. Where two regimes were compared in the same study, the effectiveness
 138 of the two regimes is joined by a line. (B) The additional protection (odds ratio) provided by a two-
 139 dose regime compared to a one dose regime. The combined estimates (black) are the medians of the
 140 posterior distribution (circle) with the 95% credible intervals (error bars).


141
 142

143 Vaccinia-binding titers in vaccinated individuals

144 To investigate the immunogenicity of different vaccination strategies, we aggregated data on
 145 the geometric mean vaccinia-binding titers (GMT) reported 4 weeks after 1 dose MVA-BN
 146 and 2 weeks after 2 dose MVA-BN. Our analysis aggregated data from studies that used
 147 slightly different ELISA assay protocols to estimate antibody titers (Table S2). We fit a
 148 Bayesian model with covariates for vaccine formulation and ELISA assay used, and a
 149 hierarchical structure to account for interstudy variability (see Methods, Table S4).

150 Interestingly, we found no significant effect of the ELISA assay used to measure the GMT
 151 (fig. S3a), but the formulation of the vaccine had a significant effect on the antibody titer
 152 (freeze dried formulation provided higher titers than liquid frozen, $p < 0.001$) (fig. S3b). Since
 153 the liquid frozen formulation was the formulation deployed in the effectiveness studies, we
 154 focus our analysis on this formulation. After accounting for all study and formulation
 155 differences, we found that the GMT induced by one dose of liquid frozen MVA-BN provides
 156 a higher antibody level than that observed in individuals who received a first-generation
 157 vaccine historically (GMT = 87.2 (CI: 66.9-115) vs 58.7 (CI: 41.4-82.2), fold difference 1.49
 158 (CI: 1.16-1.92)), and a second dose of liquid frozen MVA-BN provided a significant boost
 159 over a single dose (8.42-fold (CI: 7.79-9.10) increase, fig. 2).

160



161


162 Figure 2: Comparison of the reported geometric mean vaccinia-binding titers induced by
 163 vaccination with MVA-BN and historic first-generation vaccines. The GMTs from the freeze-
 164 dried MVA-BN formulation (light-color) are significantly higher than the liquid frozen
 165 formulation (dark-color) (1.32-fold, CI: 1.20-1.48, $p < 0.001$). Horizontal lines indicate the

166 combined estimate (median of the posterior distribution) for each vaccination and
167 formulation (dashed lines are the 95% credible intervals).

168
169

170 **Estimating a quantitative relationship between vaccinia-binding titers and vaccine** 171 **effectiveness**

172 Antibody titers are thought to be a surrogate of vaccine effectiveness for both smallpox and
173 Mpox infection^{14,37}, and were used to support the regulatory approval of MVA-BN¹³. This is
174 supported by animal studies showing an important role of antibodies in protection from
175 Mpox¹⁴. Thus, we sought to investigate the relationship between vaccinia-binding antibody
176 titer and effectiveness by combining the available immunogenicity data and effectiveness
177 data. No study found in our searches contained both effectiveness data and immunogenicity
178 data from the same cohort. Therefore, we matched the immunogenicity data to the
179 corresponding vaccine effectiveness data by vaccine regimen. That is, 1-dose MVA-BN
180 vaccination (n=10 immunogenicity, and n=6 effectiveness studies, respectively), 2-dose
181 MVA-BN vaccination (n=11, and n=4) and historic first-generation smallpox vaccination
182 (n=3, and n=5). Although we have very limited data to assess a correlation (i.e. only three
183 vaccine groups across 14 effectiveness and 13 immunogenicity studies), fitting a logistic
184 relationship between antibody titers in these groups and effectiveness (following the
185 approach used in COVID-19^{38,39}) (fig. 3), we found evidence of a significant positive
186 association between antibody titers and effectiveness (OR: 0.62 (CI 0.47-0.82) for each 10-
187 fold change in vaccinia-binding, $p < 0.001$) (Table S5). This supports the use of vaccinia-
188 binding titers as a correlate of vaccinia-based vaccine effectiveness. Further, this model
189 provides a quantitative method to predict vaccine effectiveness (along with credible intervals)
190 associated with different antibody titers and waning immunity.



191

192 Figure 3: Relationship between vaccine effectiveness and the vaccinia-binding GMT. The global
193 estimates of vaccine effectiveness and vaccinia-binding titers across different vaccination regimes are
194 shown with colored contour lines. The contours represent the lines of equal probability of the
195 normalized joint-posterior density (combining posterior densities from the vaccine immunogenicity
196 and effectiveness analyses, i.e. fig. 1 and 2, respectively). The association between antibody titers and
197 effectiveness (solid black line) is fitted using all of the underlying data (accounting for the interstudy
198 heterogeneity using a hierarchical model structure) (Table S5). The solid black line indicates the best
199 estimate (median of posterior), and shaded region show the 95% credible intervals of the predicted
200 effectiveness at different GMTs.

201

202

203 **Boosting and waning of antibody titers with MVA-BN vaccination**

204 A major question regarding Mpox control is how to optimize vaccine distribution and dosing
205 intervals in the context of a potential future outbreak. Estimates of both the durability of
206 protection and of the effects of the interval between first and second dose of MVA-BN would
207 be informative in guiding policy for future responses. The immunogenicity studies we
208 identified included a subset of studies that reported long-term follow up of antibody titers
209 after MVA-BN vaccination (up to 24 months), as well as the effects of different timing of a
210 second MVA-BN dose^{24,25,27-36}. To explore the effect of dose timing on the peak and
211 durability of antibody responses, we fitted a two-phase antibody decay model to the available
212 vaccinia-titers over time for different vaccination regimens (fig. 4a). From this analysis we
213 firstly noted, consistent with other vaccines⁴⁰, increased spacing between MVA-BN vaccine
214 doses led to a higher peak antibody response (measured at 14 days post-last dose or 28 days
215 post-initial dose, whichever is later) (fig. 4b). For example, delaying the timing of the second


216 dose from 7 days to 28 days led to a 4.2-fold (CI: 2.1-8.8) higher antibody titer. Delay from
217 28 days to 730 days led to a 3.2-fold (CI:2.6-3.8) higher titer. Interestingly, the peak antibody
218 titer after a second dose of MVA-BN at 730 days was very similar to the peak titer of a third
219 dose of MVA-BN at 730 days (after an initial 28 day-spaced two-dose regime) (GMR 1.03,
220 CI:0.82-1.31).

221 Regarding decay, we observed a fast initial decay and slow long-term decay of antibody titers
222 (i.e. model comparison indicates that a two-phase decay model is superior to a single-phase
223 decay, Table S7), and the estimated half-life of the fast-decaying and slow-decaying antibody
224 titer was 20.7 (CI:18.2-24.0) days and 1721 (CI:971-6459) days, respectively. The estimated
225 decay rates of the fast and slow-decaying antibodies were not different between the regimes
226 (Table S7). However, the initial antibody titer and proportion of slow-decaying (long-lived)
227 antibodies varied between groups (fig. 4 and S4, discussed below). Interestingly, the
228 proportion of long-lived antibodies increased in individuals with a 730-day spacing between
229 first and second dose, when compared with the standard two dose schedule (fig. S4 & Table
230 S8). Thus, when we consider the predicted antibody titers one year after boosting, delaying
231 the second dose to 730 days provides a 17.0 (CI: 13.5-21.2) fold higher titer compared to
232 standard boosting at 28 days (fig. 4c and Table S8). Interestingly, whether vaccination at 730
233 days was given as a second booster, or as a third booster (after a second at 28 days), the
234 durability of the response was similar (GMR 1 year after peak of 3 doses to 2 doses: 1.2
235 (CI:0.89-1.63)).

236

237 Of note, we estimate that antibody titers after 2 doses of MVA-BN vaccination (with 28-day
238 interval) remain above or equal to the peak GMT of one dose for 81 days (CI:72-93) and
239 above historically vaccinated cohorts for 102 days (CI: 74-173). By delaying the second dose
240 to two years, antibody titers remain above the one-dose peak for 13.2 years (CI:7.5-48.3
241 years). Together these results suggest that a delayed booster or third dose provides higher and
242 more durable antibody titers.

243



244

245 Figure 4: Predicting the durability of protection: (A) The decay in GMT in the different
 246 immunogenicity trials as fitted using a two-phase decay model. The estimated GMT (solid lines) and
 247 95% credible intervals (shaded) are shown over the two-year period for which immunogenicity data
 248 was measured in the one and two dose schedules. (B) The effect of delayed dosing. The GMT at the
 249 approximate peak (2 weeks after the final dose or 28 days after the first dose, whichever is later) is
 250 shown for different MVA-BN vaccination regimes. (C) The predicted GMT one-year post-
 251 vaccination, accounting for the early fast-decay and the late slow-decay of antibodies (Table S8).
 252 Predicted GMTs for regimens without a datapoint later than 5 months post-vaccination are faded.
 253 (D) The predicted vaccine effectiveness over a 10-year period for the different vaccination schedules. The

254 grey region highlights the prediction extrapolated beyond the available time course of
255 immunogenicity data. The three-dose schedule involves vaccination on day 28 and 2 years after the
256 initial dose (3rd dose delivered on day 730).

257

258

259 **Predicting vaccine effectiveness**

260 Using the decay kinetics of antibody titers estimated above (fig. 4a), and the logistic
261 relationship between antibody titers and vaccine effectiveness (fig. 3), we can predict the
262 duration of vaccine protection under different vaccine schedules (fig. 4d). Our analysis
263 predicts vaccination with one dose of MVA-BN will have an effectiveness of 66.6%
264 (CI:51.87-77.7) at 2 years post vaccination (note that this VE estimate is an extrapolation
265 below the range of data in fig. 3). A two-dose regimen on a 4-week schedule is anticipated to
266 still provide 73.2% (CI:61.9-81.4) effectiveness from Mpox infection at 2 years.

267 Extrapolating antibody decay beyond the available time series (shaded region in fig. 4d), we
268 also predict the level of long-term effectiveness from 1 and 2-dose MVA-BN vaccination
269 (with 28-day spacing) after 10 years will be 61.3% (CI: 42.6-75.4) and 68.4% (CI:53.0-78.9),
270 respectively. This is based on the conservative assumption that antibody decay continues at
271 the same rate over 10 years (although studies of antibody decay after first generation vaccinia
272 vaccination suggest the half-life may continue to slow to as long as 99 years³⁷). If the second
273 vaccination is delayed to 730 days, then the predicted effectiveness at 10 years post-boost is
274 78.6% (CI:68.7-85.8). Together this analysis predicts long-term protection against Mpox after
275 1, and especially 2 doses of MVA-BN vaccination.

276

277 **Discussion**

278 The ongoing spread of Mpox in West and Central Africa, the 2022 global pandemic, and the
279 associated changing epidemiology of Mpox virus highlight the importance of an improved
280 understanding of Mpox vaccination and immunity. Novel vaccinia-based vaccines were
281 anticipated to be as effective against Mpox as historical first-generation smallpox vaccines^{5,7}.
282 However, determining the efficacy of novel Mpox vaccines has proved challenging due to the
283 difficulties in performing large randomized controlled trials (RCTs). In lieu of RCTs, a
284 correlate of protection from immunogenicity data can be used in the vaccine development
285 process. Neutralizing antibody titers have been proposed as a correlate due to their role in
286 protection from a lethal Mpox challenge in animal models¹⁴. Subsequently, neutralizing
287 antibodies and animal studies formed the basis for the approval of MVA-BN as a third-
288 generation smallpox and Mpox vaccine¹³.

289 In this work we aggregate the available data to study the relationship between vaccine
290 immunogenicity and vaccine protection from Mpox infection. Analysis of the vaccine
291 effectiveness data indicates that single dose MVA-BN is non-inferior to historical vaccination
292 with first generation smallpox vaccines (OR = 1.09, (CI:0.55-2.47)). These findings support
293 the choice to adopt MVA-BN vaccine for control of Mpox given its comparable effectiveness
294 to first generation vaccines, and its beneficial safety profile³². Further, our meta-analysis
295 finds 2 dose MVA-BN vaccination to be more effective than 1 dose (OR=0.69 (CI: 0.54-
296 0.86)).

297 A validated surrogate marker of Mpox immunity would greatly assist in vaccine development
298 and deployment, and in predicting the longevity of protection and necessity for boosting.
299 Here we find a weak but significant association between antibody titers and vaccine
300 effectiveness, albeit with very limited data. The significance of this association is
301 predominantly influenced by the result that 2 doses of MVA-BN has both higher
302 effectiveness and higher antibody titers than 1 dose. Caution is required before interpreting
303 this result as a demonstration of antibody titers as a correlate of protection for vaccinia
304 vaccines against Mpox, since we have limited data available, a small range in observed
305 effectiveness, and large interstudy variation. Our observation, however, supports the existing
306 results from animal models that antibodies may be a correlate of protection against Mpox¹⁴.
307 If we assume that antibody titers are indeed a correlate, our model provides confidence limits
308 for the long-term effectiveness given the available data. A major challenge during the 2022
309 global Mpox outbreak was prioritizing the use of the small pool of existing MVA-BN

310 vaccines. In particular, it was unclear whether improved overall outcomes would be achieved
311 by, 1) maximizing the number of individuals who could receive a first dose, thus giving them
312 some protection, or 2) focusing on maximizing the number of individuals who could receive
313 the full two dose regimen and ensure they had a sufficient immunological response for
314 protection. Our analysis suggests that 2-doses of the vaccine provide only a slight increase in
315 effectiveness compared to 1-dose (82.2% vs 74.2%). Therefore, in the context of a limited
316 number of available doses, the increase in protection provided by a second dose (to recently
317 vaccinated individuals) is less than the protection that could be obtained by giving a single
318 dose to as many naïve individuals as possible. Assuming a population with equal risk, 1.81-
319 times (CI:1.58-1.93) more cases could be averted by giving a single dose to twice as many
320 individuals rather than a full 2 doses to a smaller group.

321
322 Initially administering a single dose to the maximum number of people and delaying a second
323 dose until there is increased availability of vaccine may provide additional benefits in terms
324 of the durability of protection. For example, delaying a second dose until 2 years after the
325 first dose is expected to provide a 3.2-fold higher peak titer and 14.1-fold higher titer at 1
326 year (compared to a second dose at 28 days) (fig. 4a). Even though delaying a second dose
327 produces a longer period of lower protection before boosting, protection from a single dose of
328 MVA-BN is predicted to remain >65% at 2 years (compared to 72% at 2 years for a 2-dose
329 regime) (fig. 4d). Further work is required to understand the optimal spacing of booster doses
330 to maximize both short and long-term protection. However, these data predict that
331 administering single doses initially allows the deployment of the vaccine more rapidly to
332 more individuals during an emergency, and by delaying the second dose there is a potential
333 advantage to the long-term durability of protection.

334 Our analysis includes a significant number of limitations. Firstly, the studies on vaccine
335 effectiveness show a large amount of study heterogeneity (Table S1). For example, the
336 estimated vaccine effectiveness after one dose of MVA-BN varies between 35.8% (CI:22.1-
337 47.1)¹⁶ to 86.4% (CI:83.3-89.0)¹⁷. This is perhaps not surprising, given the effectiveness data
338 was obtained from observational studies with different study designs and potential
339 confounders.

340 A major challenge in using non-randomized studies is appropriate matching of control groups
341 (in case-control studies) and identification of the at-risk population (in case-coverage
342 studies). Differences in matching cases to controls significantly affect the reported levels of
343 protection^{15,16,19}. In addition, large case-coverage studies attribute the reduction in case

344 numbers to vaccination, but this may not control for confounders such as differences in
345 behavior (which have been associated with a reduction in spread in Italy prior to the
346 commencement of vaccination⁴¹). These confounders may contribute to the substantial
347 heterogeneity in VE observed across studies (fig. 1). We can partially account for
348 unmeasured confounding by using a hierarchical model to account for inter-study variability,
349 but systematic biases that result from unmeasured confounding are unable to be completely
350 excluded.

351 Further, the route and dose of MVA-BN administered varied over time and in different
352 regions. For example, during the 2022 outbreak, following changes in FDA recommendations
353 in the US, 45.9% of individuals received their first dose (and 85.7% received their second
354 dose) via an intradermal (ID) injection of 2×10^7 TCID, instead of the per label
355 recommendation of 1×10^8 TCID administered subcutaneously (SC)⁴². Our analysis of the
356 effectiveness data could not test whether protection was impacted by the method of
357 administration since the effectiveness studies did not disaggregate data by mode of
358 administration (SC or ID). However, Panye et al.¹⁷, who tested for a difference in VE
359 between individuals who received SC and those who received ID, reported no difference.

360
361 Another limitation is that the VE data and immunogenicity data came from independent
362 cohorts and studies. Thus, there is no guarantee that the populations are well matched.
363 Specifically, there is a significant mismatch in the demographics of the vaccine effectiveness
364 studies and the immunogenicity trials. For example, the population considered in the US
365 study for vaccine effectiveness¹⁷ considered only men (sex assigned at birth or gender
366 identity) aged between 18-49. On the other hand, the clinical trials of antibody responses post
367 vaccination were all tested on populations of both men and women and featured slightly
368 different age ranges. Further, even though the majority (85.7%) of individuals in the US
369 received their second dose of MVA-BN via intradermal administration⁴², the majority of the
370 available immunogenicity data was from individuals with SC administration (creating a
371 potential mismatch in the effectiveness data and immunogenicity data). Fortunately,
372 immunogenicity data suggests similar antibody titers between the two modes of
373 administration²⁴. An additional difference between immunogenicity and effectiveness studies
374 was in the time between vaccination and serum sampling and effectiveness assessment.
375 Whereas immunogenicity was assessed at 4 or 2 weeks after first or second vaccination
376 respectively, the time from vaccination to infection is only reported in one study (Wolff Sagy
377 et al.¹⁸, where 3 of 5 infections occur in week 3, and the other two infections occur in week

378 6). A mismatch also exists in comparing historic first-generation vaccination. The
379 effectiveness data are from studies in the Democratic Republic of Congo in the 1980s to
380 2010s, whereas the immunogenicity data are from individuals in the United States (who in
381 most cases were vaccinated >40 years earlier). As well as differences in the viral clades
382 between these outbreaks^{43,44}, timing of previous vaccination in the historic vaccine
383 effectiveness studies is not recorded and may not be well matched to the immunogenicity
384 studies. Evidence of a very slow long-term decay of antibodies^{37,45-47} suggests that time-
385 since-vaccination may not be critical in comparing these groups many years after vaccination.
386 However, it was not possible to match for age of vaccination, health status, or other
387 demographic variables and their effects on immunogenicity and protection are unknown.
388 Previous work has shown that vaccination in childhood confers longer protection than
389 vaccination in adulthood⁴⁸. Further investigation of the risk of breakthrough infection in
390 historically smallpox vaccinated cohorts are required to confirm this assumption and improve
391 our understanding of the duration of Mpox immunity from vaccinia vaccines⁴⁹.

392

393 Finally, it is important to emphasize that we identified a relationship between vaccinia-
394 binding titers and vaccine protection. Although vaccinia-binding titers are correlated with in
395 vitro neutralizing antibody titers to Mpox²¹, they are likely not an optimal measure of
396 antibody effectiveness against Mpox. Further work is necessary to compare different
397 measures of immunogenicity to better standardize assays to define a correlate of protection
398 for Mpox.

399

400 This study brings together the limited and heterogenous data available on immunogenicity
401 and protection from Mpox after MVA-BN vaccination. We report non-inferiority of MVA-
402 BN against Mpox compared to historic first-generation smallpox vaccination and define a
403 candidate surrogate of vaccine effectiveness based on vaccinia-binding titers. We then use that
404 surrogate to predict the duration of vaccine effectiveness. We predict that, since long-term
405 vaccinia specific titers remain high, MVA-BN vaccine effectiveness will remain >60% for up
406 to 10 years, even after a single dose. This prediction of durable immune responses is
407 consistent with reports of first and second generation vaccines against smallpox, where
408 detectable immune responses and protection (particularly from severe infection) are thought
409 to persist for over 20 years⁵⁰⁻⁵² (reviewed in Kunasekaran et al⁴⁸). Our approach allows the
410 prediction of vaccine effectiveness based on the existing available evidence, but also
411 indicates the urgent need for further studies of MVA-BN immunogenicity and protection.

412 The development of a standardized assay for Mpox antibody binding or neutralization and a
413 serological standard for comparison are important priorities. In the absence of this,
414 comparison between studies by normalizing antibody levels to those induced by (for
415 example) 1 dose MVA-BN vaccination (similar to methods used in COVID-19^{38,39}) is
416 possible but not ideal. In addition, public health plans for a potential future Mpox outbreak
417 need to be developed, ideally informed by the best available evidence for vaccine
418 effectiveness.

419 References

- 420 1 Di Giulio, D. B. & Eckburg, P. B. Human monkeypox: an emerging zoonosis. *Lancet Infect Dis*
421 **4**, 15-25 (2004). [https://doi.org:10.1016/s1473-3099\(03\)00856-9](https://doi.org/10.1016/s1473-3099(03)00856-9)
- 422 2 Beer, E. M. & Rao, V. B. A systematic review of the epidemiology of human monkeypox
423 outbreaks and implications for outbreak strategy. *PLoS Negl Trop Dis* **13**, e0007791 (2019).
424 [https://doi.org:10.1371/journal.pntd.0007791](https://doi.org/10.1371/journal.pntd.0007791)
- 425 3 Nguyen, P. Y., Ajisegiri, W. S., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Reemergence
426 of Human Monkeypox and Declining Population Immunity in the Context of Urbanization,
427 Nigeria, 2017-2020. *Emerg Infect Dis* **27**, 1007-1014 (2021).
428 [https://doi.org:10.3201/eid2704.203569](https://doi.org/10.3201/eid2704.203569)
- 429 4 WHO Emergency Response Team. Multi-country outbreak of mpox, External situation
430 report#29. (2023). [https://www.who.int/publications/m/item/multi-country-outbreak-of-
431 mpox--external-situation-report-29---20-october-2023](https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report-29---20-october-2023)
- 432 5 Fine, P. E., Jezek, Z., Grab, B. & Dixon, H. The transmission potential of monkeypox virus in
433 human populations. *Int J Epidemiol* **17**, 643-650 (1988). [https://doi.org:10.1093/ije/17.3.643](https://doi.org/10.1093/ije/17.3.643)
- 434 6 Jezek, Z. *et al.* Four generations of probable person-to-person transmission of human
435 monkeypox. *Am J Epidemiol* **123**, 1004-1012 (1986).
436 [https://doi.org:10.1093/oxfordjournals.aje.a114328](https://doi.org/10.1093/oxfordjournals.aje.a114328)
- 437 7 Jezek, Z., Grab, B., Szczeniowski, M. V., Paluku, K. M. & Mutombo, M. Human monkeypox:
438 secondary attack rates. *Bull World Health Organ* **66**, 465-470 (1988).
- 439 8 Jezek, Z. *et al.* Human monkeypox: a study of 2,510 contacts of 214 patients. *J Infect Dis* **154**,
440 551-555 (1986). [https://doi.org:10.1093/infdis/154.4.551](https://doi.org/10.1093/infdis/154.4.551)
- 441 9 Rimoin, A. W. *et al.* Major increase in human monkeypox incidence 30 years after smallpox
442 vaccination campaigns cease in the Democratic Republic of Congo. *Proc Natl Acad Sci U S A*
443 **107**, 16262-16267 (2010). [https://doi.org:10.1073/pnas.1005769107](https://doi.org/10.1073/pnas.1005769107)
- 444 10 Nolen, L. D. *et al.* Introduction of Monkeypox into a Community and Household: Risk Factors
445 and Zoonotic Reservoirs in the Democratic Republic of the Congo. *Am J Trop Med Hyg* **93**,
446 410-415 (2015). [https://doi.org:10.4269/ajtmh.15-0168](https://doi.org/10.4269/ajtmh.15-0168)
- 447 11 Whitehouse, E. R. *et al.* Clinical and Epidemiological Findings from Enhanced Monkeypox
448 Surveillance in Tshuapa Province, Democratic Republic of the Congo During 2011-2015. *J*
449 *Infect Dis* **223**, 1870-1878 (2021). [https://doi.org:10.1093/infdis/jiab133](https://doi.org/10.1093/infdis/jiab133)
- 450 12 Eckart, R. E. *et al.* Incidence and follow-up of inflammatory cardiac complications after
451 smallpox vaccination. *J Am Coll Cardiol* **44**, 201-205 (2004).
452 [https://doi.org:10.1016/j.jacc.2004.05.004](https://doi.org/10.1016/j.jacc.2004.05.004)
- 453 13 Summary Basis for Regulatory Action-Jynneos (US FDA,2019);
454 <https://www.fda.gov/media/131802/download>
- 455 14 Edghill-Smith, Y. *et al.* Smallpox vaccine-induced antibodies are necessary and sufficient for
456 protection against monkeypox virus. *Nat Med* **11**, 740-747 (2005).
457 [https://doi.org:10.1038/nm1261](https://doi.org/10.1038/nm1261)
- 458 15 Dalton, A. F. *et al.* Estimated Effectiveness of JYNNEOS Vaccine in Preventing Mpox: A
459 Multijurisdictional Case-Control Study — United States, August 19, 2022–March 31, 2023.
460 *MMWR. Morbidity and Mortality Weekly Report* **72**, 553-558 (2023).
461 [https://doi.org:10.15585/mmwr.mm7220a3](https://doi.org/10.15585/mmwr.mm7220a3)
- 462 16 Deputy, N. P. *et al.* Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United
463 States. *N Engl J Med* **388**, 2434-2443 (2023). [https://doi.org:10.1056/NEJMoa2215201](https://doi.org/10.1056/NEJMoa2215201)
- 464 17 Payne, A. B. *et al.* Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine
465 Compared with Risk Among Unvaccinated Persons—43 US Jurisdictions, July 31-October 1,
466 2022. *Mmwr-Morbidity and Mortality Weekly Report* **71**, 1560-1564 (2022).
- 467 18 Wolff Sagy, Y. *et al.* Real-world effectiveness of a single dose of mpox vaccine in males. *Nat*
468 *Med* **29**, 748-752 (2023). [https://doi.org:10.1038/s41591-023-02229-3](https://doi.org/10.1038/s41591-023-02229-3)

- 469 19 Rosenberg, E. S. *et al.* Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection
470 — New York, 2022. *MMWR. Morbidity and Mortality Weekly Report* **72**, 559-563 (2023).
471 <https://doi.org/10.15585/mmwr.mm7220a4>
- 472 20 Bertran, M. *et al.* Effectiveness of one dose of MVA-BN smallpox vaccine against mpox in
473 England using the case-coverage method: an observational study. *Lancet Infect Dis* **23**, 828-
474 835 (2023). [https://doi.org/10.1016/S1473-3099\(23\)00057-9](https://doi.org/10.1016/S1473-3099(23)00057-9)
- 475 21 Zaeck, L. M. *et al.* Low levels of monkeypox virus-neutralizing antibodies after MVA-BN
476 vaccination in healthy individuals. *Nat Med* **29**, 270-278 (2023).
477 <https://doi.org/10.1038/s41591-022-02090-w>
- 478 22 Payne, A. B. *et al.* Incidence of Monkeypox Among Unvaccinated Persons Compared with
479 Persons Receiving ≥ 1 JYNNEOS Vaccine Dose — 32 U.S. Jurisdictions, July 31–September 3,
480 2022. *MMWR. Morbidity and Mortality Weekly Report* **71**, 1278-1282 (2022).
481 <https://doi.org/10.15585/mmwr.mm7140e3>
- 482 23 Frey, S. E. *et al.* Human Antibody Responses Following Vaccinia Immunization Using Protein
483 Microarrays and Correlation With Cell-Mediated Immunity and Antibody-Dependent Cellular
484 Cytotoxicity Responses. *J Infect Dis* **224**, 1372-1382 (2021).
485 <https://doi.org/10.1093/infdis/jiab111>
- 486 24 Frey, S. E. *et al.* Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA)
487 formulations and subcutaneous versus intradermal routes of administration in healthy
488 vaccinia-naive subjects. *Vaccine* **33**, 5225-5234 (2015).
489 <https://doi.org/10.1016/j.vaccine.2015.06.075>
- 490 25 Frey, S. E. *et al.* Safety and immunogenicity of IMVAMUNE(R) smallpox vaccine using
491 different strategies for a post event scenario. *Vaccine* **31**, 3025-3033 (2013).
492 <https://doi.org/10.1016/j.vaccine.2013.04.050>
- 493 26 Greenberg, R. N. *et al.* A Randomized, Double-Blind, Placebo-Controlled Phase II Trial
494 Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine
495 (MVA-BN(R)) in 56-80-Year-Old Subjects. *PLoS One* **11**, e0157335 (2016).
496 <https://doi.org/10.1371/journal.pone.0157335>
- 497 27 Greenberg, R. N. *et al.* A Multicenter, Open-Label, Controlled Phase II Study to Evaluate
498 Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old
499 Subjects with Diagnosed Atopic Dermatitis. *PLoS One* **10**, e0138348 (2015).
500 <https://doi.org/10.1371/journal.pone.0138348>
- 501 28 Ilchmann, H. *et al.* One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian
502 Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox
503 Vaccines. *J Infect Dis* **227**, 1203-1213 (2023). <https://doi.org/10.1093/infdis/jiac455>
- 504 29 Jackson, L. A. *et al.* Safety and immunogenicity of a modified vaccinia Ankara vaccine using
505 three immunization schedules and two modes of delivery: A randomized clinical non-
506 inferiority trial. *Vaccine* **35**, 1675-1682 (2017). <https://doi.org/10.1016/j.vaccine.2017.02.032>
- 507 30 Overton, E. T. *et al.* Immunogenicity and safety of three consecutive production lots of the
508 non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled
509 phase III trial. *PLoS One* **13**, e0195897 (2018). <https://doi.org/10.1371/journal.pone.0195897>
- 510 31 Overton, E. T. *et al.* Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic
511 Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-
512 Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial. *Open Forum Infect Dis*
513 **2**, ofv040 (2015). <https://doi.org/10.1093/ofid/ofv040>
- 514 32 Pittman, P. R. *et al.* Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against
515 Smallpox. *N Engl J Med* **381**, 1897-1908 (2019). <https://doi.org/10.1056/NEJMoa1817307>
- 516 33 Overton, E. *et al.* A randomized phase 3 trial to assess the immunogenicity and safety of 3
517 consecutively produced lots of freeze-dried MVA-BN(R) vaccine in healthy adults. *Vaccine*
518 **41**, 397-406 (2023). <https://doi.org/10.1016/j.vaccine.2022.10.056>

- 519 34 Zitzmann-Roth, E. M. *et al.* Cardiac safety of Modified Vaccinia Ankara for vaccination
520 against smallpox in a young, healthy study population. *PLoS One* **10**, e0122653 (2015).
521 <https://doi.org/10.1371/journal.pone.0122653>
- 522 35 von Krempelhuber, A. *et al.* A randomized, double-blind, dose-finding Phase II study to
523 evaluate immunogenicity and safety of the third generation smallpox vaccine candidate
524 IMVAMUNE. *Vaccine* **28**, 1209-1216 (2010). <https://doi.org/10.1016/j.vaccine.2009.11.030>
525 36 Bavarian Nordic. *A Phase II Trial to Compare a Liquid-frozen and a Freeze-dried Formulation*
526 *of IMVAMUNE (MVA-BN®) Smallpox Vaccine in Vaccinia-naïve Healthy Subjects*,
527 <<https://clinicaltrials.gov/study/NCT01668537>> (2020).
- 528 37 Amanna, I. J., Carlson, N. E. & Slifka, M. K. Duration of humoral immunity to common viral
529 and vaccine antigens. *N Engl J Med* **357**, 1903-1915 (2007).
530 <https://doi.org/10.1056/NEJMoa066092>
- 531 38 Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection
532 from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205-1211 (2021).
533 <https://doi.org/10.1038/s41591-021-01377-8>
- 534 39 Stadler, E. *et al.* Monoclonal antibody levels and protection from COVID-19. *Nat Commun* **14**,
535 4545 (2023). <https://doi.org/10.1038/s41467-023-40204-1>
- 536 40 Voysey, M. *et al.* Single-dose administration and the influence of the timing of the booster
537 dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled
538 analysis of four randomised trials. *Lancet* **397**, 881-891 (2021).
539 [https://doi.org/10.1016/S0140-6736\(21\)00432-3](https://doi.org/10.1016/S0140-6736(21)00432-3)
- 540 41 Vairo, F. *et al.* The possible effect of sociobehavioral factors and public health actions on the
541 mpox epidemic slowdown. *International Journal of Infectious Diseases* **130**, 83-85 (2023).
542 <https://doi.org/10.1016/j.ijid.2023.03.005>
- 543 42 Owens, L. E. *et al.* JYNNEOS Vaccination Coverage Among Persons at Risk for Mpox — United
544 States, May 22, 2022–January 31, 2023. *MMWR. Morbidity and Mortality Weekly Report* **72**,
545 342-347 (2023). <https://doi.org/10.15585/mmwr.mm7213a4>
- 546 43 Azzi, A. Unusual Monkeypox virus outbreak in 2022: Phenotypic and molecular
547 characteristics. *Aspects of Molecular Medicine* **1** (2023).
548 <https://doi.org/10.1016/j.amolm.2023.100001>
- 549 44 Gigante, C. M. *et al.* Multiple lineages of monkeypox virus detected in the United States,
550 2021–2022. *Science* **378**, 560-565 (2022). <https://doi.org/doi:10.1126/science.add4153>
- 551 45 Sanz-Munoz, I. *et al.* Possible Mpox Protection from Smallpox Vaccine-Generated Antibodies
552 among Older Adults. *Emerg Infect Dis* **29**, 656-658 (2023).
553 <https://doi.org/10.3201/eid2903.221231>
- 554 46 Antia, A. *et al.* Heterogeneity and longevity of antibody memory to viruses and vaccines.
555 *PLoS Biol* **16**, e2006601 (2018). <https://doi.org/10.1371/journal.pbio.2006601>
- 556 47 Hammarlund, E. *et al.* Multiple diagnostic techniques identify previously vaccinated
557 individuals with protective immunity against monkeypox. *Nat Med* **11**, 1005-1011 (2005).
558 <https://doi.org/10.1038/nm1273>
- 559 48 Kunasekaran, M. P., Chen, X., Costantino, V., Chughtai, A. A. & MacIntyre, C. R. Evidence for
560 Residual Immunity to Smallpox After Vaccination and Implications for Re-emergence. *Mil*
561 *Med* **184**, e668-e679 (2019). <https://doi.org/10.1093/milmed/usz181>
- 562 49 Jamard, S. *et al.* Resurgence of symptomatic Mpox among vaccinated patients: First clues
563 from a new-onset local cluster. *Infect Dis Now* **53**, 104714 (2023).
564 <https://doi.org/10.1016/j.idnow.2023.104714>
- 565 50 Eichner, M. Analysis of historical data suggests long-lasting protective effects of smallpox
566 vaccination. *Am J Epidemiol* **158**, 717-723 (2003). <https://doi.org/10.1093/aje/kwg225>
- 567 51 Nishiura, H. & Eichner, M. Estimation of the Duration of Vaccine-induced Residual Protection
568 Against Severe and Fatal Smallpox Based on Secondary Vaccination Failure. *Infection* **34**,
569 241-246 (2006). <https://doi.org/10.1007/s15010-006-6603-5>

570 52 Nishiura, H., Schwehm, M. & Eichner, M. Still protected against smallpox? Estimation of the
571 duration of vaccine-induced immunity against smallpox. *Epidemiology* **17**, 576-581 (2006).
572 [https://doi.org:10.1097/01.ede.0000229196.41862.c2](https://doi.org/10.1097/01.ede.0000229196.41862.c2)
573 53 Bunge, E. M. *et al.* The changing epidemiology of human monkeypox-A potential threat? A
574 systematic review. *PLoS Negl Trop Dis* **16**, e0010141 (2022).
575 [https://doi.org:10.1371/journal.pntd.0010141](https://doi.org/10.1371/journal.pntd.0010141)
576 54 WebPlotDigitizer v. 4.6 (2022). <https://automeris.io/WebPlotDigitizer>
577 55 RStan: The R interface to Stan v. 2.26.23 (2023). <https://mc-stan.org/>
578 56 Stan Modeling Language Users Guide and Reference Manual v. 2.23 (2023). <https://mc->
579 [stan.org](https://mc-stan.org)
580 57 Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine
581 effectiveness. *Vaccine* **31**, 2165-2168 (2013). [https://doi.org:10.1016/j.vaccine.2013.02.053](https://doi.org/10.1016/j.vaccine.2013.02.053)
582

583 **Methods**

584 **Search strategy**

585 We aimed to aggregate the available data that reported on both vaccine protection against
586 Mpox infection and vaccine immunogenicity in order to understand the relationship between
587 immunogenicity and protection. For vaccine protection studies, we used a recently published
588 systematic review⁵³ and extended this here. To obtain matching immunogenicity data, we
589 performed a systematic search of ClinicalTrials.gov for all studies of MVA-BN
590 immunogenicity.

591

592 *Search Strategy for vaccine effectiveness data*

593 Our search strategy for identifying studies of vaccine effectiveness was based upon the search
594 strategy in the systematic review by Bunge et al.⁵³. This systematic review identified articles
595 relating to Mpox prior to 7th September 2020. We extend this by conducting a systematic
596 search from that date up to 10th July 2023 using the same search strategy, with the following
597 modifications:

- 598 - included Mpox[tiab] to account for the recent name change,
- 599 - we added the search terms AND (Vaccine[tiab] OR Vaccination[tiab]), since our
600 search results are only targeted towards vaccine effectiveness (rather than all studies
601 reporting on Mpox).

602 For inclusion in our analysis, a study needed to report Mpox incidence data by vaccination
603 status along with an estimate, or the data required for estimating, the at-risk population for
604 observational studies, or a control group in case-control studies.

605

606 *Search strategy for Immunogenicity*

607 Since vaccinia-binding IgG antibody titers after MVA-BN vaccination have been shown to be
608 highly correlated with neutralizing antibodies against vaccinia and Mpox viruses²¹, and
609 because of the limited data on *in vitro* neutralization of Mpox virus, we focused our search of
610 immunogenicity data on vaccinia-binding titers. The immunogenicity data was obtained by
611 searching through the clinicaltrials.gov database for clinical trials using the MVA-BN
612 vaccine. We searched for intervention trials with 'MVA' as the intervention with condition,
613 'smallpox OR Monkeypox OR Variola'. We only considered studies that had been
614 completed. For inclusion in our analysis, the intervention had to be MVA-BN (different types
615 of MVA vaccines have been tested in the past but are not used for immunization against

616 Mpox). Our analysis only considers healthy individuals. Therefore, at least one arm in the
617 trial had to include a healthy population for the trial to be included in our analysis.

618

619 **Data extraction**

620 For data on vaccine effectiveness, we extracted the case/control incidence (number of events)
621 data reported in each study disaggregated by timepoint, age or region where possible. For
622 immunogenicity data, we contacted the sponsor by e-mail to request access to the de-
623 identified individual-level data presented in the published work. This request was denied (27
624 March 2023). Therefore, we extracted summary data (Geometric Mean Titer (GMT) and
625 confidence intervals (CI)) from tables (where available) or figures using WebPlotDigitiser⁵⁴.
626 Where data was extracted from an image, two individuals (MB, SRK) extracted the data
627 independently with the geometric mean of the two extracted values used and we confirmed
628 that discrepancies between extracted values were always less than 1%.

629

630 **Statistical analysis**

631 All meta-analyses and meta-regression were performed using a hierarchical Bayesian data
632 analysis framework in RStan^{55,56} using the default HMC sampler. This included global
633 estimates of mean effectiveness, and antibody titers after vaccination, estimates of the decay
634 kinetics of antibody titers, and fitting the relationship between antibody titers and
635 effectiveness. Hierarchical model structures were used to account for inter-study variability in
636 all analyses, and unless otherwise stated all reported estimates are posterior medians, along
637 with 95% credibility intervals (CI). To perform statistical tests of whether a parameter (or
638 difference in parameters), g , was significantly different to zero we defined a p-value, $p =$
639 $2 \times \min(P(g > 0), P(g < 0))$, which was calculated from the posterior distributions of
640 estimated parameters. Significance was defined as $p < 0.05$.

641

642 **Estimating vaccine effectiveness**

643 In our meta-analysis of vaccine effectiveness, we implement a modified version of the
644 Bayesian binomial approach^{27,28} to fit the raw event data from each study. The binomial
645 model assumes individuals in a given population, N , have an unknown probability of
646 infection, r . Therefore, the number of infections, n , follow a binomial distribution, $p(n|r) =$
647 $\text{Bin}(r, N)$, with posterior distribution,

$$648 \quad p(r | n) = \frac{p(n | r)p(r)}{p(n)}.$$

649 We use an un-informative prior on the probability of infection, i.e. $p(r) \sim \text{Beta}(1,1)$. An
650 equivalent model is used for the risk of infection after vaccination, r_v , with the vaccine
651 effectiveness $E = 1 - OR$, where OR is the odds ratio (of the risk of infection between
652 unvaccinated and vaccinated individuals). Under the assumption of a rare disease ($r \ll 1$), the
653 odds ratio, risk ratio and hazard ratio converge.

654 For all studies, we used the most temporally disaggregated data available (Table S1). This
655 allows us to better account for changes in incidence and vaccine coverage over the outbreak.
656 We also used data disaggregated by demographic factors, such as age, where available.
657 Groups or timepoints in which no cases were reported in both control and vaccinated
658 populations were excluded from the analysis. We assumed that the baseline risk of infection
659 in unvaccinated individuals could differ for temporally or spatially disaggregated groups
660 from the same study, but we assumed the vaccine effectiveness was constant. That is, for a
661 given study, s , we had pairs of data $(n_{i,v,s}, N_{i,v,s})$, where, $n_{i,v,s}$ is the number of infections and
662 $N_{i,v,s}$ the total individuals of the disaggregation group i , with vaccine v , in study s . We
663 estimate a different baseline risk in unvaccinated individuals ($v = 0$), $r_{i,0,s}$, for disaggregation
664 group i , and a fixed vaccine effectiveness E_v . The risk of infection after vaccination ($v \neq 0$)
665 is then given by,

$$\text{logit}(r_{i,v,s}) = \text{logit}(r_{i,0,s}) + \log(1 - E_v) + S_s \quad 1$$

667 where S_s is the random effect on the risk reduction from vaccination (on the logit scale) in
668 each study. These random effects are defined by the hierarchical structure $S_s \sim N(0, \sigma)$
669 (further detail in supplementary methods), where σ is to be estimated. The posterior
670 distribution is defined using the likelihood function,

$$n_{i,v,s} \sim \text{Bin}(r_{i,v,s}, N_{i,v,s}). \quad 2$$

672 and with the priors,

$$r_{i,0,s} \sim \text{Beta}(1,1),$$

$$R_v \sim N(0,10),$$

$$\sigma \sim \text{Half-Cauchy}(0.25).$$

676 For the case-control studies, the at-risk population is not used. However, vaccine
677 effectiveness can be estimated using the odds ratio comparing the odds of vaccination in the
678 infection and control groups⁵⁷. Subsequently we can use the same model (Equation 1 and 2)
679 to fit the case-control studies (detailed in Supplementary methods).

680

681

682 **Estimating immunogenicity**

683 Our goal here is to estimate the mean vaccinia-binding titer induced by vaccination in each
684 group, as well as the spread (standard deviation) of those titers between individuals (since
685 this is important when relating antibody titers to protection³⁸). That is, we aim to estimate the
686 mean, μ_v , and standard deviation, σ_v , of the distribution of antibody titers induced in a
687 population after vaccination for a given vaccine regimen, v . Since we do not have individual
688 level data from each study, we are limited to using only three pieces of data for each group,
689 from each study, to estimate these quantities. Specifically, the (log) GMT reported after
690 vaccination, $\bar{y}_{s,v,f,E}$, the number of individuals in these groups, $n_{s,v,f,E}$, and the standard
691 deviation of the (log) titers in these groups, $\overline{sd}_{s,v,f,E}$ (derived from the reported confidence
692 intervals, Supplementary Methods) – in each study, s , and for each vaccine group, v
693 (accounting for different assays, E , and vaccine formulations, f). We assume that
694 individuals' (log) vaccinia-binding titers after vaccination are normally distributed, i.e.

$$695 \quad y_{i,s,v,f,E} \sim N(\mu_v + \mu_s + \mu_f + \mu_E, \sigma_v),$$

696 where the mean and standard deviation of titers after vaccination with vaccine v are μ_v and
697 σ_v (respectively), and assuming this mean is influenced by: (i) random study effects, μ_s (from
698 a hierarchical model structure, where $\mu_s \sim N(0, \sigma_s)$, and σ_s , is also a parameter that is
699 inferred), (ii) a fixed effect, μ_f , to account for potential differences in antibody titers induced
700 by the two different vaccine formulations used for the MVA-BN vaccine (freeze dried and
701 liquid frozen), and (iii) a fixed effect, μ_E , to account for the effect of the different ELISA
702 assays (but the latter was not a significant covariate, and removed from further analysis). We
703 use the above model to estimate the distribution of the participant level vaccinia-binding
704 titers, using the sample mean, $\bar{y}_{s,v,f,E}$, and sample standard deviation, $\overline{sd}_{s,v,f,E}$ from each
705 group/study as 'sufficient statistics' to estimate this distribution (i.e. we require no other
706 information to estimate the participant level distribution of vaccinia-binding titers other than
707 the available sample means and standard deviations - derivation in supplementary material,
708 including likelihood function). We impose the below weakly informative priors on our
709 parameters,

$$710 \quad \mu_d \sim N(0,10)$$

$$711 \quad \log(\sigma_d) \sim N(0,10)$$

$$712 \quad \mu_E \sim N(0,10)$$

$$713 \quad \mu_f \sim N(0,10)$$

$$714 \quad \sigma_s \sim \text{Half-Cauchy}(0,1).$$

715

716 When antibody titers were below the limit of detection, this was handled in different ways
717 across the different studies. Some studies had assigned values of “1” to the titers below the
718 detection limit before calculating the GMT, whilst other studies assigned those values as half
719 the limit of detection. For consistency in our analysis, we adjusted the GMTs from the latter
720 studies to reflect the former approach. That is, we used the reported number of seropositive
721 samples (those above the limit of detection) to adjust GMTs from each study such that values
722 below the limit of detection were set to “1”.

723

724 **Predicting vaccine effectiveness over time**

725 We fit a model of biphasic exponential decay to the vaccinia-binding antibody titers. This
726 model has two compartments, long (x_l) and short (x_s) lived antibody titers, which each are
727 assumed to decay with rates δ_l and δ_s , respectively. Thus, the total antibody titer at time, t , is
728 given by $x(t) = x_l(t) + x_s(t)$, where,

$$729 \quad x_s(t) = x_0 f e^{-\delta_s t},$$

$$730 \quad x_l(t) = x_0 (1 - f) e^{-\delta_l t},$$

731 and where x_0 is the antibody titer at $t = 0$ (which is defined as a maximum of 14 days after
732 final dose or 28 days after the first dose), and f is the fraction of the initial antibody titer that
733 is short-lived. After model comparison (Table S7), we found that the decay rates δ_l and δ_s
734 are not significantly different between dosing regimens. However, we assume the initial
735 antibody titer (x_0) and the fraction short-lived, f , differs for each dosing regimen and is also
736 different for historically vaccinated groups. The log (base 10) of the model and data were
737 fitted in RStan as described above in the “Estimating immunogenicity” section. We impose
738 the weakly informative priors on the decay model parameters.

$$739 \quad \delta_s, \delta_l \sim N(0,1)$$

$$740 \quad f \sim U(0,1)$$

741

742 **Fitting the relationship between vaccinia binding antibody titers and protection from** 743 **Mpox**

744 To analyse the relation between antibody titers and protection we applied a model we have
745 previously used to identify a correlate of protection for COVID-19³⁸. The model assumes that
746 there is a logistic relationship between the protection, P , experienced by a group of
747 individuals with a given vaccinia-binding antibody titer, x , given by,

748
$$P(x) = \frac{1}{1 + e^{-k(x-x_{50})}},$$

749 where, x_{50} is the 50% protective titer and k describes the steepness of the relation between
750 the antibody titer and the protection.

751 We re-parameterize this function with the substitution, $A = -k(2.5 - x_{50})$, to provide better
752 numerical stability during model fitting, in cases where the two parameters trade-off, i.e.

753
$$P(x) = \frac{1}{1 + e^{-k(x-2.5)-A}}.$$

754 For a given vaccinated population, we must consider the observed population distribution of
755 vaccinia-specific antibody titers (with mean μ and standard deviation σ). The average
756 protection over the distribution of titers is given by,

757
$$VE = \int_{-\infty}^{\infty} P(x)N(x | \mu, \sigma) dx$$

758 where $N(x|\mu, \sigma)$ denotes the probability density function of the normal distribution. The data
759 on antibody titers and effectiveness are fitted simultaneously to estimate all model parameters
760 along with associated credible intervals (Table S5). The priors used and hierarchical structure
761 (to account for inter-study variability) are also provided in Table S6.

762

763 **Ethics statement**

764 This work was approved under the UNSW Sydney Human Research Ethics Committee
765 (approval HC200242).

766 **Conflicts of interest**

767 CRM is on the WHO SAGE Working Group on Smallpox and Monkeypox. The authors have
768 no other competing interests to declare.

769 **Funding**

770 This work is supported by an NHMRC program grant GNT1149990 (to MPD), Investigator
771 grants (GNT1173931 to AEG, GNT2016907 to CRM and GNT1173027 to MPD) and an
772 NHMRC Centre for Research Excellence BREATHE (GNT2006595). DSK is supported by a
773 University of New South Wales fellowship.

774 The funders had no role in the design and conduct of the study; collection, management,
775 analysis, and interpretation of the data; preparation, review, or approval of the manuscript;
776 and decision to submit the manuscript for publication.

777 **Data and code availability**

778 Extracted data and codes for analysis will be made publicly available on GitHub upon
779 publication.

780